Renal Cell Carcinoma - Pipeline Review, H1 2012

Renal Cell Carcinoma – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Renal Cell Carcinoma - Pipeline Review, H1 2012', provides an overview of the Renal Cell Carcinoma therapeutic pipeline. This report provides information on the therapeutic development for Renal Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma. 'Renal Cell Carcinoma - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Renal Cell Carcinoma.
- A review of the Renal Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Renal Cell Carcinoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Renal Cell Carcinoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Renal Cell Carcinoma pipeline depth and focus of Renal Cell Carcinoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Renal Cell Carcinoma Therapeutic Products under Development, Key Players in Renal Cell Carcinoma Therapeutics, Renal Cell Carcinoma Pipeline Overview, Renal Cell Carcinoma Pipeline, Renal Cell Carcinoma Pipeline Assessment SHOW LESS READ MORE >

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Renal Cell Carcinoma Overview
Therapeutics Development
An Overview of Pipeline Products for Renal Cell Carcinoma
Renal Cell Carcinoma Therapeutics under Development by Companies
Renal Cell Carcinoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Renal Cell Carcinoma Therapeutics – Products under Development by Companies
Renal Cell Carcinoma Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Renal Cell Carcinoma Therapeutics Development
Bristol-Myers Squibb Company
Genzyme Corporation
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Kyowa Hakko Kirin Co., Ltd.
Amgen Inc.
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Seattle Genetics, Inc.
Genentech, Inc.
Emergent BioSolutions Inc.
Oxford BioMedica plc
Novartis AG
ImClone Systems Incorporated
Astellas Pharma Inc.
Eisai Co., Ltd.
Ono Pharmaceutical Co., Ltd.
OSI Pharmaceuticals, Inc.
Pfizer Inc.
Taiho Pharmaceutical Co., Ltd.
Exelixis, Inc.
Celgene Corporation
Bayer AG
MannKind Corporation
3SBio Inc.
EntreMed, Inc.
Celldex Therapeutics, Inc.
Active Biotech AB
Lorus Therapeutics Inc
Bionomics Limited
Northwest Biotherapeutics, Inc.
Cleveland BioLabs, Inc.
Flamel Technologies S.A.
Dendreon Corporation
MOLOGEN AG
OncoTherapy Science, Inc.
Threshold Pharmaceuticals, Inc.
Rexahn Pharmaceuticals, Inc.
Antisense Pharma GmbH
Wilex AG
Philogen S.p.A.
immatics biotechnologies GmbH
Curacyte AG
Argos Therapeutics, Inc.
Cytheris SA
AgrenVec, S.L.
MacroGenics, Inc.
Pivotal BioSciences, Inc.
Jennerex Biotherapeutics, Inc.
Endocyte, Inc.
Advenchen Laboratories, LLC
Immutep S.A.
Syndax Pharmaceuticals, Inc.
Tigris Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc.
Advanced Cancer Therapeutics
Renal Cell Carcinoma – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Axitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Axitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sutent - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ANYARA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMA901 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TroVax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NuLeusin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tivozanib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rencarex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dovitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aldesleukin for Kidney Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + Torisel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Interferon Alfa-2B + Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Interferon Alfa-2B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sunitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Interferon Alfa + CCI-779 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TroVax + IL-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Interferon-Alpha - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Everolimus + Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ANYARA + Interferon Alpha - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sunitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Interferon-alpha - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Interleukin 2 + Interferon-alpha2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sorafenib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sorafenib + Sunitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Gamma Interferon - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + Interferon Alfa-2a - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Renal Cell Carcinoma Therapeutics – Drug Profile Updates
Renal Cell Carcinoma Therapeutics – Discontinued Products
Renal Cell Carcinoma Therapeutics - Dormant Products
Renal Cell Carcinoma – Product Development Milestones
Featured News & Press Releases
Jan 03, 2012: AVEO And Astellas Announce Positive Phase III Trial Results Of Tivozanid In Comparision With Sorafenib For Treatmant Of Renal Cell Cancer
Dec 07, 2011: FDA Advisory Committee Finds Benefit/Risk Profile Of Axitinib In Previously Treated Advanced Renal Cell Carcinoma To Be Favorable
Nov 21, 2011: MOLOGEN Attains Goals Of Renal Cancer Study With MGN1601 Ahead Of Schedule
Nov 21, 2011: IDMC Recommends Conducting Final Analysis Of Pivotal Phase III Trial With WILEX's RENCAREX
Nov 03, 2011: AVEO To Present Tivozanib Clinical Data At Upcoming Oncology Medical Congresses
Oct 05, 2011: FDA Grants Fast Track Designation To WILEX’s RENCAREX For Adjuvant Therapy Of Clear Cell Renal Cell Carcinoma
Sep 13, 2011: Pfizer To Present Clinical Data On Axitinib Portfolio At 2011 European Multidisciplinary Cancer Congress
Sep 13, 2011: Bayer And Onyx Announce Presentation Of New Nexavar Data At 2011 ECCO-ESMO Congress
Sep 13, 2011: Bayer To Present New Data On Regorafenib At 2011 ECCO-ESMO Congress
Sep 13, 2011: Pfizer To Present Clinical Data On SUTENT At 2011 European Multidisciplinary Cancer Congress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Renal Cell Carcinoma, H1 2012
Products under Development for Renal Cell Carcinoma – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Development by Companies, H1 2012 (Contd..2)
Number of Products under Development by Companies, H1 2012 (Contd..3)
Number of Products under Development by Companies, H1 2012 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..6)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Development by Companies, H1 2012 (Contd..1)
Products under Development by Companies, H1 2012 (Contd..2)
Products under Development by Companies, H1 2012 (Contd..3)
Products under Development by Companies, H1 2012 (Contd..4)
Products under Development by Companies, H1 2012 (Contd..5)
Products under Investigation by Universities/Institutes, H1 2012
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..9)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..10)
Bristol-Myers Squibb Company, H1 2012
Genzyme Corporation, H1 2012
Boehringer Ingelheim GmbH, H1 2012
F. Hoffmann-La Roche Ltd., H1 2012
Kyowa Hakko Kirin Co., Ltd., H1 2012
Amgen Inc., H1 2012
AstraZeneca PLC, H1 2012
Eli Lilly and Company, H1 2012
GlaxoSmithKline plc, H1 2012
Seattle Genetics, Inc., H1 2012
Genentech, Inc., H1 2012
Emergent BioSolutions Inc., H1 2012
Oxford BioMedica plc, H1 2012
Novartis AG, H1 2012
ImClone Systems Incorporated, H1 2012
Astellas Pharma Inc., H1 2012
Eisai Co., Ltd., H1 2012
Ono Pharmaceutical Co., Ltd., H1 2012
OSI Pharmaceuticals, Inc., H1 2012
Pfizer Inc., H1 2012
Taiho Pharmaceutical Co., Ltd., H1 2012
Exelixis, Inc., H1 2012
Celgene Corporation, H1 2012
Bayer AG, H1 2012
MannKind Corporation, H1 2012
3SBio Inc., H1 2012
EntreMed, Inc., H1 2012
Celldex Therapeutics, Inc., H1 2012
Active Biotech AB, H1 2012
Lorus Therapeutics Inc, H1 2012
Bionomics Limited, H1 2012
Northwest Biotherapeutics, Inc., H1 2012
Cleveland BioLabs, Inc., H1 2012
Flamel Technologies S.A., H1 2012
Dendreon Corporation, H1 2012
MOLOGEN AG, H1 2012
OncoTherapy Science, Inc., H1 2012
Threshold Pharmaceuticals, Inc., H1 2012
Rexahn Pharmaceuticals, Inc., H1 2012
Antisense Pharma GmbH, H1 2012
Wilex AG, H1 2012
Philogen S.p.A., H1 2012
immatics biotechnologies GmbH, H1 2012
Curacyte AG, H1 2012
Argos Therapeutics, Inc., H1 2012
Cytheris SA, H1 2012
AgrenVec, S.L., H1 2012
MacroGenics, Inc., H1 2012
Pivotal BioSciences, Inc., H1 2012
Jennerex Biotherapeutics, Inc., H1 2012
Endocyte, Inc., H1 2012
Advenchen Laboratories, LLC, H1 2012
Immutep S.A., H1 2012
Syndax Pharmaceuticals, Inc., H1 2012
Tigris Pharmaceuticals, Inc., H1 2012
AVEO Pharmaceuticals, Inc., H1 2012
Advanced Cancer Therapeutics, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Renal Cell Carcinoma Therapeutics – Drug Profile Updates
Renal Cell Carcinoma Therapeutics – Discontinued Products
Renal Cell Carcinoma Therapeutics – Discontinued Products (Contd..1)
Renal Cell Carcinoma Therapeutics – Dormant Products
Renal Cell Carcinoma Therapeutics – Dormant Products (Contd..1)
Renal Cell Carcinoma Therapeutics – Dormant Products (Contd..2)
Renal Cell Carcinoma Therapeutics – Dormant Products (Contd..3)
Renal Cell Carcinoma Therapeutics – Dormant Products (Contd..4)
Renal Cell Carcinoma Therapeutics – Dormant Products (Contd..5)
Renal Cell Carcinoma Therapeutics – Dormant Products (Contd..6)
Renal Cell Carcinoma Therapeutics – Dormant Products (Contd..7)
Renal Cell Carcinoma Therapeutics – Dormant Products (Contd..8)
Renal Cell Carcinoma Therapeutics – Dormant Products (Contd..9)
Renal Cell Carcinoma Therapeutics – Dormant Products (Contd..10)
Renal Cell Carcinoma Therapeutics – Dormant Products (Contd..11)

List of Figures
Number of Products under Development for Renal Cell Carcinoma, H1 2012
Products under Development for Renal Cell Carcinoma – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012